Repurposed drug could save transplanted lungs
NCT ID NCT06853223
Summary
This study is testing if a drug called Maraviroc can prevent a dangerous complication called primary graft dysfunction (PGD) after a lung transplant. PGD is a major cause of early death and has no approved treatment. About 120 adult lung transplant patients at high risk for PGD will receive either Maraviroc or a placebo for 3 days after surgery to see if it reduces severe lung injury.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NATURAL KILLER CELL MEDIATED IMMUNITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.